Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

US National OCS Liver Perfusion (OLP) Registry

NCT05940857 · View on ClinicalTrials.gov ↗

Study Summary

This Registry is a sponsor-initiated, multi-center, observational, post-approval registry with an independent academic oversight. TransMedics has contracted with United Network for Organ Sharing (UNOS) the Federal manager of the U.S. national transplant outcomes registry to obtain data that is routinely collected by the Organ Procurement and Transplantation Network (OPTN) on all transplanted organs in the U.S. for both the OCS liver transplanted patients as well as patients transplanted using other preservation modalities. Additional data will be collected by participating centers using OCS Liver perfusion.

Conditions Studied

Interventions

  • DEVICE OCS Liver

Study Locations (20)

California

  • University of California San Diego — La Jolla
  • University of California San Francisco — San Francisco

Massachusetts

  • Beth Israel Deaconess Medical Center — Boston
  • Lahey Clinic Medical Center — Burlington

Michigan

  • University of Michigan Medical Center — Ann Arbor
  • Henry Ford Hospital — Detroit

North Carolina

  • Carolinas Medical Center/Atrium Health — Charlotte
  • Duke Medical Center — Durham

Texas

  • UT Southwestern Medical Center — Dallas
  • Houston Methodist — Houston

Alabama

  • University of Alabama — Birmingham

Arizona

  • Mayo Clinic Hospital Arizona — Phoenix

Florida

  • Mayo Clinic Hospital Florida — Jacksonville

Trial Details

FieldValue
Enrollment Target 100,000 participants
Start Date 2021-10-14
Est. Completion 2031-10

Sponsor

TransMedics

16 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05940857

The ClinicalTrials.gov registry entry for NCT05940857 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TransMedics, which has 16 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Liver Transplant appearing as the primary indexed condition, and to 1 intervention — of which OCS Liver is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05940857 reports 20 study locations spanning 15 distinct geographic areas — top geographies include California, Massachusetts, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05940857 about?

NCT05940857 is a clinical study titled "US National OCS Liver Perfusion (OLP) Registry". This Registry is a sponsor-initiated, multi-center, observational, post-approval registry with an independent academic oversight. TransMedics has contracted with United Network for Organ Sharing (UNOS) the Federal manager of the U.S. national transplant outcomes registry to obtain data that is rout...

What is the current status of trial NCT05940857?

This trial is currently recruiting. The enrollment target is 100,000 participants. The study started on 2021-10-14. Estimated completion is 2031-10.

What conditions does trial NCT05940857 study?

This clinical trial studies the following conditions: Liver Transplant. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05940857?

The interventions under investigation include: OCS Liver (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05940857?

This trial is sponsored by TransMedics, which has 16 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05940857 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial